Novocure Ltd (NVCR NASDAQ) stock market data APIs
$12.7002
-0.1(-0.8%)
as of September 17, 2025
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
12.7002
Open
12.6008
High
13.3125
Low
12.5446
52 wk Range
10.87-34.13
Market Cap
1 418 M
Shares Outstanding
112 M
Revenue
630 M
EPS
-0.36
Beta
0.583
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novocure Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 630 M
- EBITDA: -158 863 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-24
- EPS/Forecast: -0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo
NovoCure recently secured approval for its Optune Lua® device in Japan, a milestone for the company’s TTFields therapy that targets non-small cell lung cancer. This development aligns with the comp...
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry...
Insider Spends US$997k Buying More Shares In NovoCure
NovoCure Limited (NASDAQ:NVCR) shareholders (or potential shareholders) will be happy to see that the CEO & Director, Ashley Cordova, recently bought a whopping US$997k worth of stock, at a price of U...
NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed?
Spain's Ministry of Health recently made NovoCure's Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System for adults with newly diagnosed glioblastoma, expandin...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
